Eiger BioPharmaceuticals Inc

OTC Pink - Current Information:EIGRQUnited States

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its portfolio also includes avexitide, a well-characterized GLP-1 antagonist, as a targeted treatment for two metabolic diseases with high unmet medical needs. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, Peginterferon Lambda (lambda) for COVID-19, Avexitide for Congenital Hyperinsulinism (HI) and Avexitide for Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection.

Contact Information

Headquarters

2155 Park BlvdPALO ALTO, CA, United States 94306-1543

Phone

650-279-9845

Fax

650-618-1621

Executives

Independent Chairman of the Board

Thomas Dietz

Chief Executive Officer, Director

David Apelian

Chief Financial Officer

William Kachioff

Chief Compliance Officer, General Counsel, Corporate Secretary

James Vollins

Independent Director

Lisa Kelly-Croswell